Advertisement

Managing paroxysmal atrial tachycardias in patients with pacemakers

  • Richard Sutton
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 183)

Abstract

Paroxysmal atrial tachycardias may demand the full extent of both clinical acumen and pacemaker technology for optimal management. This field has grown in the last decade from a basic recognition of the existence of the problem [1] to a sophisticated armamentarium of technological solutions for widely appreciated and frequent phenomena. At first, only a few centres realised the benefits of atrial pacing in sinoatrial node disease for prevention of its serious complications, notably stroke, other systemic emboli and heart failure [2–5]. In the second half of the 1980s and the 1990s the real value of atrial pacing has been established [6, 7] culminating in the report of the Danish trial [8] where atrial versus ventricular pacing in sinoatrial node disease was studied prospectively and showed conclusive evidence of the superiority of atrial pacing in reduction of systemic embolism. The principles underlying these reports are applicable to the management of all patients paced for sinoatrial node disease and to some extent in those with a different aetiology.

Keywords

Mode Switching Ventricular Pace Atrial Tachycardia Atrial Pace Chronic Atrial Fibrillation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sutton R, Kenny RA. The natural history of sick sinus syndrome PACE 1986; 9: 1110–4.PubMedGoogle Scholar
  2. 2.
    Santini M, Rocchi M, Alliegro A, Masini V. Atrial and AV sequential pacing benefits and reliability. In Feruglio G (ed): Cardiac pacing, electrophysiology and pacemaker technology. Padova: Piccin 1982; 693–8.Google Scholar
  3. 3.
    Witte J. The behaviour of atrioventricular conduction after implantation of AAI pacemakers. PACE 1983; 6: Al [Abstract].Google Scholar
  4. 4.
    Rosenqvist M, Brandt J, Schüller H. Atrial versus ventricular pacing in sinus node disease. A treatment comparison study. Am Heart J 1986; 111; 292–297.Google Scholar
  5. 5.
    Altamura G, Boccadamo R, Antonini L, Toscano S, Roncella A, Pistolese M. Treatment of the bradycardia-tachycardia syndrome: comparative analysis between atrial and ventricular pacing. In Feruglio G (ed): Cardiac pacing, electrophysiology and pacemaker technology. Padova: Piccin 1982; 511–4.Google Scholar
  6. 6.
    Rosenqvist M, Brandt J, Schüller H. Long term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J 1988; 116: 16–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Santini M, Alexidou G, Ansalone G et al. Relation of prognosis in sick sinus syndrome to age, conduction defects and modes of permanent cardiac pacing. Am J Cardiol 1990; 65: 729–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Andersen HR, Theusen L, Bagger JP, Bloch Thomsen PE. Prospective randomised trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994; 344: 1523–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kulbertus HE. Atrial fibrillation: epidemiologic aspects and natural history. In Kulbertus HE, Wellens HJJ, Bourgeois IMGP, Sutton R (eds): Atrial fibrillation: facts from yesterday-ideas for tomorrow. Armonk NY: Futura Publishing Co. Inc 1994; 1–14.Google Scholar
  10. 10.
    Sutton R, Bourgeois I. Cost effectiveness of VVI versus DDD pacing in sick sinus syndrome. PACE 1995; 18: 1192 [Abstract].Google Scholar
  11. 11.
    Castellanet M, Florio J, Messenger J. DDI: a new mode for cardiac pacing. Clin Prog Pacing Electrophysiol 1984; 2: 255–60.Google Scholar
  12. 12.
    Kato R, Terasawa T, Gotoh T, Suzuki M. Antiarrhythmic efficacy of atrial demand [AAI] and rate responsive atrial pacing. In Santini M, Pistolese M, Alliegro A (eds): Prog Clin Pacing. Amsterdam: Excerpta Medica 1988: 15–24.Google Scholar
  13. 13.
    Bellocci F, Nobile A, Spampinato A et al. Antiarrhythmic effects of DDD rate responsive pacing. PACE 1991; 14: 622. [Abstract].Google Scholar
  14. 14.
    Sowton E, Leatham A, Carson P. The suppression of arrhythmias by artificial pacemaking. Lancet 1964; 2: 1098–100.PubMedCrossRefGoogle Scholar
  15. 15.
    Bana G, Locatelli V, Piatti L, Gerosa C, Knippel M. DDI pacing in the bradycardia-tachycardia syndrome. PACE 1990; 13: 264–70.PubMedGoogle Scholar
  16. 16.
    Sutton R. Evaluation of DDD pacing with and without atrial tachy response in patients with sick sinus syndrome. Eur J Cardiac Pacing Electrophysiol 1995; 5: 49–53.Google Scholar
  17. 17.
    Kay GN, Plumb VJ, Arciniegas JG et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observation in 32 patients. J Am Coll Cardiol 1983; 2: 806–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Leclerq JF, Maisonblanche P, Cauchemez B, Coumel P. Respective role of sympathetic tone and of cardiac pauses in the genesis of 62 cases of ventricular fibrillation recorded during Holter monitoring. Eur Heart J 1988; 9: 1276–83.Google Scholar
  19. 19.
    Brugada P, Goethals M, Timmermans W. Can atrial fibrillation be prevented by pacing algorithms? Eur J Cardiac Pacing Electrophysiol 1994; 4(Suppl 3): 31–4.Google Scholar
  20. 20.
    Daubert C, Mabo P, Berder V, Gras D, Leclerq C. Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronisation. Eur J Cardiac Pacing Electrophysiol 1994; 4(Suppl 3): 35–44.Google Scholar
  21. 21.
    Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study. Circulation 1991; 84: 527–39.Google Scholar
  22. 22.
    The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11.CrossRefGoogle Scholar
  23. 23.
    Connolly SJ, Laupacis A, Gent M et al. Canadian atrial fibrillation anticoagulation [CAFA] study. J Am Coll Cardiol 1991; 18: 349–55.PubMedCrossRefGoogle Scholar
  24. 24.
    Petersen P, Godtfredsen J, Boysen G et al. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; 1: 175–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Ezekowitz MD, Bridges SL, James KE et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. Veterans Affairs stroke prevention in non-rheumatic atrial fibrillation investigators. N Engl J Med 1992; 327: 1406–12.PubMedCrossRefGoogle Scholar
  26. 26.
    European atrial fibrillation trial [EAFT] study group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62.Google Scholar
  27. 27.
    Murgatroyd FD, Johnson EE, Cooper RA et al. Safety of low energy transvenous atrial defibrillation — World experience. Circulation 1994; 90: I. 14 [Abstract].Google Scholar
  28. 28.
    Cox JL, Boineau JP, Schleusser RB et al Successful surgical treatment of atrial fibrillation. IV: Surgical technique. J Thorac Cardiovasc Surg 1991; 101: 584.PubMedGoogle Scholar
  29. 29.
    Swartz JF, Pellersels G, Silvers J et al. A catheter based curative approach to atrial fibrillation in humans. Circulation 1994; 90: I-335 [Abstract].Google Scholar
  30. 30.
    Saoudi N, Derumeaux G, Cribier A, Letac B. The role of catheter ablation techniques in the treatment of classic [type 1] atrial flutter. PACE 1991; 14: 2022–7.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Richard Sutton

There are no affiliations available

Personalised recommendations